Kiniksa Pharmaceuticals International, plc KNSA R3KPHARMA
Company Overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Why Investors Should Care
Revenue has grown at a 104.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $677.56M (+60.1% YoY); net profit $59.01M.
- Trailing 12 Months Year-on-year growth — revenue +55.4%, earnings +30.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 104.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 104.76% |
| 1 Year: | 55.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 30.40% |
Stock Price Performance
| 1 Year: | +129.09% |
| 6 Months: | +64.93% |
| 3 Months: | +57.20% |
| 1 Month: | +1.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.19 · Neutral
P/E of 77.87 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 104.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 77.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KNSA Kiniksa Pharmaceuticals International, plc R3KPHARMA | 77.09 | 77.87 | $3.57B | 0.00% | 12.37% | 14.04% | 104.76% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 7.70M | 12.10M | 32.19M | 26.97M | 99.14M | 48.34M | 71.47M | 67.05M | 79.86M | 108.63M | 112.21M | 137.78M | 156.80M | 180.85M | 214.27M |
| Operating Income | -11.39M | -16.25M | -16.34M | -21.53M | -26.16M | -67.65M | -39.29M | -30.45M | -29.39M | -31.86M | -43.22M | -49.28M | -40.55M | -30.67M | -23.32M | -19.37M | 46.41M | -11.20M | -3.15M | -10.93M | -16.54M | -117.00K | -9.66M | 13.27M | 20.16M | 24.02M | 29.27M |
| Net Income | -11.20M | -16.03M | -15.98M | -20.26M | -24.41M | -65.82M | -37.19M | -27.06M | -26.42M | -37.47M | -43.84M | -49.48M | -41.56M | -30.54M | -25.21M | -19.98M | 224.09M | -12.27M | 14.97M | -13.86M | -17.70M | -3.91M | -12.69M | 8.54M | 17.83M | 18.43M | 22.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.72 | -0.61 | -0.44 | -0.36 | -0.29 | 3.18 | -0.18 | 0.21 | -0.20 | -0.25 | -0.06 | -0.18 | 0.11 | 0.23 | 0.23 | 0.27 |
| R&D Expense | 9.27M | 14.01M | 12.63M | 17.20M | 20.64M | 59.25M | 30.85M | 22.01M | 20.90M | 22.32M | 31.42M | 28.68M | 23.95M | 19.24M | 20.82M | 13.80M | 16.48M | 15.17M | 23.77M | 17.11M | 26.33M | 24.02M | 26.06M | 19.32M | 18.75M | 24.17M | 27.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Operating Income | -65.40M | -108.16M | -169.96M | -157.36M | -156.64M | 9.77M | -25.20M | -45.62M | 77.22M |
| Net Income | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M | 59.01M |
| Diluted EPS | - | - | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 |
| R&D Expense | 56.36M | 86.60M | 135.00M | 112.04M | 99.30M | 65.49M | 76.10M | 111.62M | 96.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.49M | 321.96M | 254.53M | 349.46M | 232.80M | 459.67M | 526.32M | 580.55M | 763.63M |
| Total Equity | -25.73M | -89.71M | 279.27M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M | 567.61M |
| Cash & Equivalents | - | 45.55M | 71.98M | 46.93M | 114.04M | 122.47M | 122.72M | 107.95M | 183.58M | 165.60M |
| Total Liabilities | - | 17.43M | 42.70M | 29.11M | 37.53M | 47.76M | 63.52M | 87.48M | 142.12M | 196.03M |
| Current Liabilities | - | 17.43M | 42.55M | 27.83M | 31.85M | 44.82M | 47.07M | 63.67M | 100.62M | 139.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -50.22M | -81.01M | -158.37M | -136.53M | -126.30M | 5.81M | 13.30M | 25.69M | 137.99M |
| Investing Cash Flow | -69.00K | -239.20M | 49.21M | -23.44M | 128.63M | -8.08M | -29.56M | 37.67M | -188.99M |
| Financing Cash Flow | 39.87M | 346.74M | 84.11M | 227.09M | 5.88M | 2.52M | 1.50M | 12.27M | 33.02M |
| Capital Expenditure | -69.00K | -5.29M | -3.20M | -283.00K | -415.00K | -105.00K | -130.00K | -277.00K | -1.57M |
| Free Cash Flow | -50.29M | -86.30M | -161.57M | -136.81M | -126.71M | 5.70M | 13.17M | 25.41M | 136.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Net Margin % | - | - | - | - | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| ROE % | 72.3% | -37.0% | -71.8% | -51.7% | -85.3% | 46.3% | 3.2% | -9.9% | 10.4% |
| ROCE % | -217.6% | -38.7% | -75.0% | -49.5% | -83.3% | 2.4% | -5.4% | -9.5% | 12.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 17.30% | 6.97M | $538.47M |
| 2 | Rubric Capital Management LP | 9.92% | 4.00M | $308.94M |
| 3 | Baker Bros. Advisors, LP | 7.03% | 2.83M | $218.95M |
| 4 | Blackrock Inc. | 6.80% | 2.74M | $211.61M |
| 5 | Tang Capital Management, LLC | 5.61% | 2.26M | $174.55M |
| 6 | Vanguard Portfolio Management LLC | 4.74% | 1.91M | $147.63M |
| 7 | Vanguard Capital Management LLC | 3.38% | 1.36M | $105.11M |
| 8 | Morgan Stanley | 2.51% | 1.01M | $78.10M |
| 9 | Arrowstreet Capital, Limited Partnership | 2.38% | 957.51K | $73.96M |
| 10 | Spruce Street Capital LP | 2.28% | 918.07K | $70.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KNSA
Kiniksa sets a live healthcare talk for Sept. 9 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQazZicURlQk13VUxfaS1pMVVOaGxFbXJYaExiVzNucDBpYWZBUDYxRm05LTQ1MHg3WTF5a29MVFBGQmJLbjNNa0ZDU2lhWlpQX2JmN0QzU1hFMVRhSlpvMllLRXluZGtDLW9NYzVEeDcwMjducFRYRWJZY3hMYWk0elp1QXpmX2hSU1pOeG…
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSzlEbHlwMU1JVHN5SXpmMG0xam5JbWNQamJYNnZjWktOaWtBUHRNUlhMMGR5WmxtcmxTVWw3QTJFU1doamxmYVlra0dDUmNIU2l6MVZXZDV0TWtjbnNuVjRUR0NRd3NqTkxvVjI5alpYNVRCRzBJR0NNNjN1eDJXT1doZDczV04yX3QyWG…
Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPTXVDQWQ4U0hyNEgyVU84ek5EN185dm9BTzFodEx4aWVESm5wcFhFQk9tb25mY1VZRjZzS0thR3AxRTQzN1l2dUtzQUI1TTRXNEVFYS00MnJITFRJbUR4bEprZ0JPaHBMOXJ0X3VzTkJWbUF3dzQ3VjlZR0lseUNweG9zS1FoSko1UTVEVF…
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPODJLSW8wS1dYWHk2MmwwczFRd2x5REQ4aEgxcUNtOExVemtxaHpab3VkRkFnR0NZbFJsZ2J5cnVIaUpEdWswdmJiOFJPZ1lMeUVtNTFobE5saktXQVRiQjNmQ2VCaW5Dc29ZLUVZdHFtbHJZdmVVcHU0cEFYaGNVdVFYckplR2R0MTZRZD…
$KNSA stock is up 21% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNUlQwTkRmYXMzQnZuV0Y2UjJCOTlwN1NpSTZpN1BJZzJZNWNSQzlBTTFjUHhfcFZWek9rdE80M0NSUUVlc3ZZUmZTZTFLcHVQS3F6RFRnb3FJeHdLNUVyTzVrT2lQa1VuSFpMS3M5aG0wSjN1aDBMcTM5VnVYWXE3U3FvM25Hcms1ZG1MSD…
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup - ChartMill
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPdHRBdUlCbzFyQ2taNXdsTWhyaVRVQVNHUDN4eGdZb0dEazB5UDY2VmFPb2NWVzlCamE5V1ozUGlURG9OOWR4dG9PdkVTdUJwN0lPck9HQkt2SmxNOVlsc3AzSjRKRkFRS0tKWlFwa1ExdFlDM1Q1ejhzV1JVSW5CU2VIZFJZajBfaUFjaG…
KNSA — Frequently Asked Questions
What is the current share price of Kiniksa Pharmaceuticals International, plc (KNSA)?
As of 2026-09-19 21:16 PDT, Kiniksa Pharmaceuticals International, plc (KNSA) trades at $77.09 on NasdaqGS. Its 52-week range is $33.04 to $80.92.
What is the market capitalisation of KNSA?
Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalisation of $3.57B on NasdaqGS.
What is the P/E ratio of KNSA?
KNSA trades at a trailing price-to-earnings (P/E) ratio of 77.87. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 9.21.
What is the return on equity (ROE) of KNSA?
KNSA has a return on equity (ROE) of 14.04%. Its return on capital employed (ROCE) is 12.37%.
Is KNSA a good stock to buy?
This page provides a data-driven analysis of Kiniksa Pharmaceuticals International, plc (KNSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.